About this episode

This episode discusses the role of bispecific T-cell engagers in the treatment of relapsed/refractory multiple myeloma.

In this week’s episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly important conversation that is so important in the current treatment landscape and one that you don’t want to miss. If you haven’t done so already, be sure to check out our CAR T episode. Content: - What are bispecific T-cell engagers? - How are they different than CAR T? - A discussion of the pivotal MajesTEC-3 trial (NEJM 2025) - What are key side effects? - How to sequence CAR T vs. bispecific T-cell engagers? ** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast ! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

Topics covered

• myeloma
• bispecific T-cell engagers
• relapsed/refractory multiple myeloma
• treatment landscape
• MajesTEC-3 trial
• CAR T therapy

Keywords

• myeloma
• bispecific T-cell engagers
• CAR T
• MajesTEC-3 trial
• treatment
• side effects
• sequencing

Sponsors

The Lymphoma, Leukemia and Myeloma Congress

Mentioned in this episode

Books & works: MajesTEC-3 trial, CAR T episode

More episodes of The Fellow on Call: The Heme/Onc Podcast

• Episode 157: Immune Thrombocytopenic Purpura Series, Pt 3- Challenging Scenarios in ITP · July 1, 2026
• Episode 156: Immune Thrombocytopenic Purpura Series, Pt 2- Relapsed/Refractory · June 24, 2026
• Episode 155: Immune Thrombocytopenic Purpura Series, Pt 1- First Line Management · June 17, 2026
• Episode 154: Ask The Program Directors-The Do’s and Don'ts of Applying to Hematology Fellowship (Career Development Series) · May 20, 2026
• Episode 153: Myeloma Capstone, Pt 2 - MRD-Guided Therapy, Maintenance, and Relapsed/Refractory Sequencing · April 22, 2026
• Episode 152: Myeloma Capstone, Pt 1 - Smoldering Myeloma & Frontline Treatment in the Elderly · April 15, 2026

Explore listener stats, chart rankings, contacts and more on the The Fellow on Call: The Heme/Onc Podcast podcast page.